Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
A new player has entered the liquid biopsy game.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
A poor quarter is followed by an acquisition, but is it big enough?